Jeanette Cueva
New York, NYNPI 1689898983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 35.6% of the total. 2025 is the largest year on record at $514, 4.2 times the $123 reported in 2019.
Across 52 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$414
- Takeda Pharmaceuticals U.S.A., Inc.$162
- Johnson & Johnson$123
- AstraZeneca$120
- Vertical Pharmaceuticals, LLC$86
- Supernus Pharmaceuticals, Inc.$72
- plus $186 from 6 others
Across 163 payments — averaging $3377.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$307K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$122K
- Alkermes, Inc.$101K
- AbbVie$14K
- Sunovion Pharmaceuticals Inc.$6K
What the payments were for
- Food & beverage$1,163100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $414 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $162 |
| Johnson & Johnson | 1 | $123 |
| AstraZeneca | 1 | $120 |
| Vertical Pharmaceuticals, LLC | 4 | $86 |
| Supernus Pharmaceuticals, Inc. | 4 | $72 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Neos Therapeutics, LP | 2 | $45 |
| Validus Pharmaceuticals LLC | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Bausch Health US, LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 13 | $837 |
| Clonazepam | 15 | $189 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.